All In Biotech

Drug Trial Radar · NCT00725985

Oral Cladribine in Early Multiple Sclerosis (MS)

A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS

Last checked: Nov 20, 2026Latest source record: Mar 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 617 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

617

Actual

Start

Dec 31, 2008

Primary completion

Jul 31, 2011

Study completion Apr 30, 2012

Sponsor

Sponsor type
Industry
First posted
Jul 31, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A randomized, double-blind, clinical trial to assess the safety and efficacy of two doses of oral cladribine versus placebo in participants who had a first clinical demyelinating event (clinically isolated syndrome). Participants in either the cladribine or placebo group may also enter treatment periods with open-label interferon-beta or open-label cladribine depending upon the disease status. The primary objective of this study is to evaluate the effect of two dosage regimens of oral cladribine versus placebo on the time to conversion to multiple sclerosis (MS) (from randomization) according to the Poser criteria in participants with first clinical demyelinating event at high risk of converting to MS.

Conditions

  • Multiple Sclerosis

Interventions

  • CladribineDrug

    Cladribine tablets were administered until CDMS conversion, whichever occur first.

  • PlaceboDrug

    Placebo matched to cladribine tablets were administered.

  • Rebif® new formulation (RNF)Drug

    Participants who converted to CDMS during ITP entered in open-label maintenance period (OLMP) and received RNF subcutaneously at a dose of 44 microgram (mcg) three times a week. Participants who converted to CDMS during long-term follow-up (LTFU) period, received RNF subcutaneously at a dose of 44 mcg three times a week.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ITP: Time to Clinically Definite Multiple Sclerosis (CDMS) Conversion Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With CDMSTime frame: ITP: Baseline up to Week 96

Locations

158 sites in 34 countries. Site status is shown where the registry gives one.

  • Hope Research Institute Medical Plaza LLC Desert Hills

    Phoenix, Arizona

  • Multiple Sclerosis Center Drive, Neurology Suite 701

    Newport Beach, California

  • University of Colorado at Denver Health Sciences

    Denver, Colorado

  • Fort Collins Neurology

    Fort Collins, Colorado

  • MS Center of Brevard MIMA Centry Research Associates

    Melbourne, Florida

  • University of South Florida

    Tampa, Florida

  • MS Center of Atlanta

    Atlanta, Georgia

  • Bruce Hughes West Building

    Des Moines, Iowa

  • Michigan Neurology Associates

    Clinton Township, Michigan

  • Henry Ford Hospital

    Detroit, Michigan

  • University of Minnesota

    Minneapolis, Minnesota

  • Dennis Dietrich

    Great Falls, Montana

  • University of Medicine and Dentistry of New Jersey School of Neurology

    Stratford, New Jersey

  • Upstate Clinical Research LLC 3

    Albany, New York

  • Neurological Specialists of Long Island

    Great Neck, New York

  • Multiple Sclerosis Center of Northeastern NY

    New York, New York

  • Comprehensive MS Care Clinic at South Shore Multiple Sclerosis

    Patchogue, New York

  • Carolinas Medical Center

    Charlotte, North Carolina

  • Meritcare Neuroscience Center Neurology

    Fargo, North Dakota

  • University of Cincinnati

    Cincinnati, Ohio

  • MS Center of Oklahoma

    Oklahoma City, Oklahoma

  • Neurology and Sleep Medicine

    Bethlehem, Pennsylvania

  • Swedish Medical Center Cherry Hill

    Seattle, Washington

  • Neurology & Neurological Association of Tacoma

    Tacoma, Washington

  • Instituto Medico Rodriguez Alfici

    Godoy Cruz, Argentina

  • Fundacion Rosarina de Neurorehabilitacion

    Rosario, Argentina

  • Krankenhaus der Barmherzigen Brüder

    Linz, Austria

  • Algemeen Ziekenhuis St Jan

    Bruges, Belgium

  • Cliniques Universitaires St-Luc

    Brussels, Belgium

  • Hopital Erasme

    Brussels, Belgium

  • CHU de Liege - Domaine Universitaire du Sart Tilman,

    Liège, Belgium

  • Clinical Center University of Sarajevo

    Sarajevo, Bosnia and Herzegovina

  • Military Medical Academy- Sofia (MMA)

    Pleven, Bulgaria

  • MBAL Rousse AD 1st

    Rousse, Bulgaria

  • Central Clinic Hospital

    Sofia, Bulgaria

  • Military Medical Academy

    Sofia, Bulgaria

  • National Heart Hospital

    Sofia, Bulgaria

  • Second MHAT

    Sofia, Bulgaria

  • Tokuda Hospital

    Sofia, Bulgaria

  • University Hospital St Naum

    Sofia, Bulgaria

Showing 40 of 158 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.